Jon Congleton, CEO of Mineralys Therapeutics Inc, sold 49,313 shares, now owning 926,958 shares. The company focuses on precision medicine for cardiovascular and kidney diseases. Insider activity shows equal buys and sells, impacting the stock's valuation and performance.